Let’s Work Side-by-Side
Our team has decades of experience discovering, optimizing, and developing antibodies against complex and challenging targets.
Get started on a project.
Twist Biopharma is committed to helping you realize the potential of your biggest biologic development programs. Wherever you are in the development pipeline, we have a solution that will elevate you to the next level of discovery
Leveraging AI in Drug Discovery
AI and machine learning algorithms are providing more accurate in silico models of the complexities of antibody-antigen interactions. When paired with Twist’s DNA synthesis, antibody expression, and functional characterization capabilities, the chances of discovering a potent and selective antibody are greatly increased.
Confident Leaders in Biopharma
Our experienced scientific team is led by CSO, Dr. Aaron Sato, Ph.D., a proven leader in the antibody therapeutics space. Over the multiple decades he’s spent in the biologics industry, he’s guided the discovery and development of first-in-class biologics, through IND filing.
Tackling Untapped Drug Targets
Many drug targets, such as GPCRs, have been labeled as undruggable. Our best-in-class discovery platform, optimization capabilities, and high-throughput developability workflow was designed to uncover lead antibodies against several hard-to-drug targets, including GLP-1R, ADORA2A, and more.